Top Medical News
14 hours ago
Resveratrol, piceatannol and analogues demonstrate a high potency both as inhibitors of androgen synthesis and androgen receptor activation, according to a study, suggesting the potential of such compounds in the chemoprevention of prostate cancer.
2 days ago
In patients with renal cell carcinoma, mean platelet volume is a highly significant risk factor for recurrence and cancer-specific death, a recent study has found. This parameter enhances the accuracy of the Leibovich prognosis score to better predict long-term outcomes in localized renal cell carcinoma cases following curative surgical resection.
3 days ago
Severity of malignancy, preoperative serum albumin concentration, intraoperative blood loss and duration of operation, among other factors, predict postoperative pneumonia (POP) development following major oral cancer (OC) surgery, a recent study has found.
4 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.
4 days ago
New drug applications approved by US FDA as of 1 - 15 November 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
5 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
Saras Ramiya, 5 days ago
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Special Reports
20 Sep 2017
Sustained stable disease with regorafenib in heavily pretreated metastatic colon cancer
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).
Prof. Ignatius Ou Sai Hong, Dr. James Suh, Dr. Wong Seng Weng, Dr. Amit Verma, 14 May 2017
As targeted cancer therapy options are increasing, it is becoming more important to choose the most appropriate treatment for patients with cancer. At a Roche-sponsored symposium held during the 2nd ESMO Asia Congress in Singapore, four experts discussed the potential of comprehensive genomic profiling (CGP) for personalizing cancer care and helping healthcare professionals to make the best treatment decisions for individual patients.
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. Fred Hirsch, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
14 Mar 2017
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.
31 Jan 2017
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
Conference Reports
Dr. Joseph Delano Fule Robles, 08 Nov 2017

Aggressive dose de-escalation of radiotherapy provides similar efficacy and superior safety profile in patients with human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC), according to a recent study presented at the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO). 

Jackey Suen, 08 Nov 2017

Hypofractionated radiotherapy (HFRT) is equally effective and safe compared with conventional fractionated RT (CFRT) in Chinese breast cancer patients who have undergone mastectomy, according to a phase III study presented at the American Society for Radiation Oncology (ASTRO) 2017 Annual Meeting. [ASTRO 2017, abstract 5]

Jackey Suen, 01 Nov 2017

Use of consolidative stereotactic ablative radiotherapy (SAbR) prior to maintenance chemotherapy improves progression-free survival (PFS) by more than 6 months in patients with non-small-cell lung cancer (NSCLC) who have limited metastases, a recent phase II study has shown. [ASTRO 2017, abstract LBA3; JAMA Oncol 2017, doi: 10.1001/jamaoncol.2017.3501]

Dr. Joseph Delano Fule Robles, 31 Oct 2017

Combination therapy with the CTLA-4 blocker, ipilimumab, and stereotactic ablative radiation therapy (SABR) is effective in cancers with metastatic lung and liver lesions, according to results presented at the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Rachel Soon, 30 Oct 2017

Integrating robust smoking cessation programs with organized low-dose CT (LDCT) lung cancer screening may decrease mortality rates while being relatively cost-effective, according to a modelling study.

Rachel Soon, 30 Oct 2017

Customizing chemotherapy (CT) treatment based on BRCA1 expression levels of post-operative patients with stage II/III non-small-cell lung cancer (NSCLC) does not affect overall survival (OS) versus standard treatment, say researchers.

Rachel Soon, 30 Oct 2017

On-the-ground education focused on changing knowledge, beliefs and attitudes towards cancer may be key to reducing disproportionately high mortality rates among underserved minority communities, say researchers.

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!